Science & Enterprise subscription

Follow us on Twitter

  • A new enterprise is starting-up to develop treatments that target cancer-causing proteins considered unreachable wi… https://t.co/g6t4Hg2kbR
    about 11 hours ago
  • New post on Science and Enterprise: Company Launches Attacking Cancer Proteins, Lands $67M https://t.co/Fl7aOMxZ5M #Science #Business
    about 11 hours ago
  • Researchers in Australia and India developed a safer and much less costly process for synthesizing the super-materi… https://t.co/Dafpsb8fhi
    about 14 hours ago
  • New post on Science and Enterprise: Safe, Economical Method Devised to Make Graphene https://t.co/LylnFSbYYM #Science #Business
    about 14 hours ago
  • An analysis of gut microbes from elite athletes identified a particular bacterial strain, which in tests with lab m… https://t.co/Nv5jCmmFDD
    about 1 day ago

Please share Science & Enterprise

Edwards Lifesciences Acquires Blood Monitor Device Company

EKG (Photos8.com)

(Photos8.com)

Edwards Lifesciences Corp., a developer of cardiac and blood monitoring technology in Irvine, California, acquired BMEYE B.V., a maker of non-invasive blood-oxygen monitors in the Netherlands. The purchase price was €32.5 million ($42.0 million).

Edwards Lifesciences designs and manufactures tissue replacement heart valves and valve repair products, as well as critical care, cardiac surgery systems, and vascular devices. The company also provides hemodynamic monitoring systems for the measurement of blood circulation and cardiac functions that allow clinicians to evaluate the volume of oxygen being delivered to tissues.

BMEYE’s monitoring products use a non-invasive finger cuff to continuously measure cardiac output, blood pressure, fluid responsiveness, and other hemodynamic data in real time. BMEYE’s products are approved for sale in the U.S., Europe, and in several other countries.

“BMEYE’s unique non-invasive technology platform complements our existing portfolio and will provide clinicians with critical, comprehensive hemodynamic monitoring information for a broader range of patients,” says Carlyn Solomon, Edwards’ vice president for critical care and vascular products. “Numerous studies have concluded that therapy guided by hemodynamic monitoring improves patient outcomes and reduces complications and lengths of hospital stays.”

Edwards Lifesciences says it plans to further develop BMEYE’s technology and integrate it into the Edwards EV1000 patient-monitoring platform for use in the acute care settings. The company says BMEYE’s products have up to now been used primarily by clinicians outside of the hospital.

Read more:

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.